S&P 500   4,669.66 (+1.63%)
DOW   35,236.12 (+0.97%)
QQQ   399.77 (+2.19%)
AAPL   160.56 (+2.39%)
MSFT   338.08 (+2.55%)
FB   338.81 (+1.71%)
GOOGL   2,911.25 (+2.38%)
AMZN   3,584.97 (+2.29%)
TSLA   1,134.46 (+4.86%)
NVDA   328.35 (+4.23%)
BABA   131.73 (-1.21%)
NIO   40.07 (+0.20%)
CGC   11.09 (-5.13%)
AMD   159.45 (+3.00%)
GE   98.76 (+0.94%)
MU   85.21 (+2.15%)
T   24.06 (-0.66%)
F   19.78 (+0.15%)
DIS   147.40 (-0.48%)
ACB   6.47 (-4.71%)
AMC   37.01 (-1.65%)
PFE   53.87 (-0.24%)
BA   198.03 (-0.59%)
S&P 500   4,669.66 (+1.63%)
DOW   35,236.12 (+0.97%)
QQQ   399.77 (+2.19%)
AAPL   160.56 (+2.39%)
MSFT   338.08 (+2.55%)
FB   338.81 (+1.71%)
GOOGL   2,911.25 (+2.38%)
AMZN   3,584.97 (+2.29%)
TSLA   1,134.46 (+4.86%)
NVDA   328.35 (+4.23%)
BABA   131.73 (-1.21%)
NIO   40.07 (+0.20%)
CGC   11.09 (-5.13%)
AMD   159.45 (+3.00%)
GE   98.76 (+0.94%)
MU   85.21 (+2.15%)
T   24.06 (-0.66%)
F   19.78 (+0.15%)
DIS   147.40 (-0.48%)
ACB   6.47 (-4.71%)
AMC   37.01 (-1.65%)
PFE   53.87 (-0.24%)
BA   198.03 (-0.59%)
S&P 500   4,669.66 (+1.63%)
DOW   35,236.12 (+0.97%)
QQQ   399.77 (+2.19%)
AAPL   160.56 (+2.39%)
MSFT   338.08 (+2.55%)
FB   338.81 (+1.71%)
GOOGL   2,911.25 (+2.38%)
AMZN   3,584.97 (+2.29%)
TSLA   1,134.46 (+4.86%)
NVDA   328.35 (+4.23%)
BABA   131.73 (-1.21%)
NIO   40.07 (+0.20%)
CGC   11.09 (-5.13%)
AMD   159.45 (+3.00%)
GE   98.76 (+0.94%)
MU   85.21 (+2.15%)
T   24.06 (-0.66%)
F   19.78 (+0.15%)
DIS   147.40 (-0.48%)
ACB   6.47 (-4.71%)
AMC   37.01 (-1.65%)
PFE   53.87 (-0.24%)
BA   198.03 (-0.59%)
S&P 500   4,669.66 (+1.63%)
DOW   35,236.12 (+0.97%)
QQQ   399.77 (+2.19%)
AAPL   160.56 (+2.39%)
MSFT   338.08 (+2.55%)
FB   338.81 (+1.71%)
GOOGL   2,911.25 (+2.38%)
AMZN   3,584.97 (+2.29%)
TSLA   1,134.46 (+4.86%)
NVDA   328.35 (+4.23%)
BABA   131.73 (-1.21%)
NIO   40.07 (+0.20%)
CGC   11.09 (-5.13%)
AMD   159.45 (+3.00%)
GE   98.76 (+0.94%)
MU   85.21 (+2.15%)
T   24.06 (-0.66%)
F   19.78 (+0.15%)
DIS   147.40 (-0.48%)
ACB   6.47 (-4.71%)
AMC   37.01 (-1.65%)
PFE   53.87 (-0.24%)
BA   198.03 (-0.59%)
NASDAQ:ERYP

ERYTECH Pharma Stock Forecast, Price & News

$2.41
-0.02 (-0.82%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.40
$2.46
50-Day Range
$2.30
$6.39
52-Week Range
$2.30
$13.00
Volume
21,382 shs
Average Volume
342,535 shs
Market Capitalization
$67.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.21
30 days | 90 days | 365 days | Advanced Chart
Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.


ERYTECH Pharma logo

About ERYTECH Pharma

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Headlines

ERYTECH Pharma S.A. (NASDAQ:ERYP) Short Interest Update
November 29, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERYP
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.25 million
Book Value
$1.51 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$67.30 million
Optionable
Not Optionable

Company Calendar

Today
11/29/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

0.90 out of 5 stars

Medical Sector

1286th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

188th out of 201 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












ERYTECH Pharma (NASDAQ:ERYP) Frequently Asked Questions

Is ERYTECH Pharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ERYTECH Pharma in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ERYTECH Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERYP, but not buy additional shares or sell existing shares.
View analyst ratings for ERYTECH Pharma
or view top-rated stocks.

How has ERYTECH Pharma's stock price been impacted by Coronavirus (COVID-19)?

ERYTECH Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ERYP stock has decreased by 54.0% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ERYTECH Pharma?

ERYTECH Pharma saw a decrease in short interest in November. As of November 15th, there was short interest totaling 8,500 shares, a decrease of 57.1% from the October 31st total of 19,800 shares. Based on an average daily volume of 93,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short.
View ERYTECH Pharma's Short Interest
.

Who are ERYTECH Pharma's key executives?

ERYTECH Pharma's management team includes the following people:
  • Gil Beyen, Chief Executive Officer & Director
  • Eric Soyer, Chief Operating & Financial Officer
  • Stewart Craig, Chief Technical Officer
  • Iman El-Hariry, Chief Medical Officer
  • Jérôme Bailly, Chief Quality Officer & Deputy General Manager

What other stocks do shareholders of ERYTECH Pharma own?

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%).

Which major investors are buying ERYTECH Pharma stock?

ERYP stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.

How do I buy shares of ERYTECH Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $2.41.

How much money does ERYTECH Pharma make?

ERYTECH Pharma has a market capitalization of $67.30 million and generates $4.25 million in revenue each year.

How many employees does ERYTECH Pharma have?

ERYTECH Pharma employs 2,020 workers across the globe.

What is ERYTECH Pharma's official website?

The official website for ERYTECH Pharma is www.erytech.com.

Where are ERYTECH Pharma's headquarters?

ERYTECH Pharma is headquartered at 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at (347) 874-4438, via email at [email protected], or via fax at 33-4-78-75-56-29.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.